Standard BioTools Inc
LAB
View Detailed Chart
1.260USD
+0.020+1.61%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
483.35MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.61%
5 Days
-10.00%
1 Month
-0.79%
6 Months
-1.56%
Year to Date
-1.56%
1 Year
-11.27%
View Detailed Chart
TradingKey Stock Score of Standard BioTools Inc
Currency: USD Updated: 2026-02-06Key Insights
Standard BioTools Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 96 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1.55.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Standard BioTools Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Standard BioTools Inc Highlights
StrengthsRisks
Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 78.09% year-on-year.
Undervalued
The company’s latest PE is -3.76, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 297.38M shares, decreasing 8.89% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 29.11K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.65.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
1.550
Target Price
+25.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Standard BioTools Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Standard BioTools Inc Info
Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
Ticker SymbolLAB
CompanyStandard BioTools Inc
CEOEgholm (Michael)
Websitehttps://www.standardbio.com/
Related Instruments
+2.98%
+0.07%
+1.60%
+2.48%
+0.31%
-1.14%
-0.05%
-2.35%
-1.78%
+2.65%
+2.59%
+2.03%
+2.01%
+2.38%
+1.74%
+0.16%
+0.78%
+1.72%
+0.59%
-2.02%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68715.610
-1254.520 (-1.79%)
282.580
+22.390 (+8.61%)
2027.940
-23.790 (-1.16%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
